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ABSTRACT 
Tamoxifen, raloxifene, and nafoxidine are selective estrogen receptor modulators (SERMs) 
reported to inhibit the catalytic activity of human aldehyde oxidase 1 (AOX1).  How these drugs 
interact with AOX1 and whether other SERMs inhibit this drug-metabolizing enzyme are not 
known.  Therefore, a detailed in vitro and in silico study involving parent drugs and their analogues 
was conducted to investigate the effect of specific SERMs, particularly acolbifene, bazedoxifene, 
and lasofoxifene on AOX1 catalytic activity, as assessed by carbazeran 4-oxidation, an AOX1-
selective catalytic marker.  The rank-order in the potency (based on IC50 values) of AOX1 
inhibition by SERMs was raloxifene > bazedoxifene ~ lasofoxifene > tamoxifen > acolbifene.  
Inhibition of liver cytosolic AOX1 by bazedoxifene, lasofoxifene, and tamoxifen was competitive, 
whereas that by raloxifene was noncompetitive.  Loss of 1-azepanylethyl group increased the 
inhibitory potency of bazedoxifene, whereas the N-oxide group decreased it.  The 7-hydroxy group 
and the substituted pyrrolidine ring attached to the tetrahydronaphthalene structure contributed to 
AOX1 inhibition by lasofoxifene.  These results are supported by molecular docking simulations 
in terms of predicted binding modes, encompassing binding orientation and efficiency, and analysis 
of key interactions, particularly hydrogen bonds.  The extent of AOX1 inhibition by bazedoxifene 
was increased by estrone sulfate and estrone.  In summary, SERMs differentially inhibited human 
AOX1 catalytic activity.  Structural features of bazedoxifene and lasofoxifene contributed to 
AOX1 inhibition, whereas those of acolbifene rendered it considerably less susceptible to AOX1 
inhibition.  Overall, our novel biochemical findings and molecular docking analyses provide new 
insights into the interaction between SERMs and AOX1.   
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Statement of Significance 
Aldehyde oxidase (AOX1) is a molybdo-flavoprotein and has emerged as a drug-metabolizing 
enzyme of potential therapeutic importance because drugs have been identified as AOX1 
substrates.  Selective estrogen receptor modulators (SERM), which are drugs used to treat and 
prevent various conditions, differentially inhibit AOX1 catalytic activity.  Structural features of 
bazedoxifene and lasofoxifene contribute to AOX1 inhibition, whereas those of acolbifene render 
it considerably less susceptible to AOX1 inhibition.  Our novel biochemical findings, together with 
molecular docking analyses, provide new insights into the differential inhibitory effect of SERMs 
on the catalytic activity of human AOX1, how SERMs bind to AOX1, and increase our 
understanding of the AOX1 pharmacophore in the inhibition of AOX1 by drugs and other 
chemicals.    
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Introduction 
Aldehyde oxidase is a member of the family of molybdo-flavoprotein, which requires 
molybdo-pterin and flavin adenine dinucleotide cofactors for its catalytic activity (Garattini and 
Terao, 2013).  In humans, there is only one isoform of aldehyde oxidase (AOX1), and the transcript 
and protein are expressed primarily in the liver and adrenal gland, and a lesser extent in other 
tissues such as the kidney and lung (Moriwaki et al., 2001; Terao et al., 2016b).  It is a phase I drug 
metabolizing enzyme that catalyzes the oxidation of a broad variety of chemical scaffolds, such as 
aldehydes, azaheterocycles, iminium ions (Pryde et al., 2010) and mediates the reduction of 
sulfoxides, N-oxides, and nitro compounds with the presence of an electron donor (Paragas et al., 
2017; Konishi et al., 2017).  Drugs such as methotrexate (Chladek et al., 1997; Kitamura et al., 
1999), famciclovir (Rashidi et al., 1997), and idelalisib (Ramanathan et al., 2016) are substrates for 
human AOX1.  The importance of AOX1 in drug metabolism is mainly due to its ability to 
metabolize azaheterocycles, which represent a common scaffold in drugs (Pryde et al., 2010).  
AOX1-catalyzed drug metabolism has led to failures in clinical trials because of its impact on drug 
clearance, resulting in unacceptable pharmacokinetic properties (Akabane et al., 2011) and renal 
toxicity (Diamond et al., 2010; Lolkema et al., 2015).  Although knockout of Aox4 in mice is not 
lethal (Terao et al., 2009; Terao et al., 2016a), the consequence of knocking out other mouse Aox 
genes is not known.  In the human, genetic polymorphisms in AOX1 affect its activity (Hartmann 
et al., 2012; Foti et al., 2017), and an association between AOX1 polymorphism and azathioprine 
dosing and response has been reported (Smith et al., 2009; Kurzawski et al., 2012).  
Selective estrogen receptor modulators (SERMs) are drugs used to treat and prevent various 
conditions, including breast cancer and postmenopausal osteoporosis (Pickar et al., 2010).  
Chemical classes of SERMs based on their backbone structures, include triphenylethylenes (e.g. 
tamoxifen, toremifene, ospemifene, droloxifene, clomifene), benzothiophenes (e.g. raloxifene, 
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arzoxifene), tetrahydronaphthalenes (e.g. nafoxidine, lasofoxifene), indoles (e.g. bazedoxifene), 
and benzopyrans (e.g. acolbifene) (Dowers et al., 2006; DeGregorio et al., 2014; Patel and Bihani, 
2018).  Raloxifene, nafoxidine, and tamoxifen have been identified as inhibitors of human liver 
cytosolic phthalazine oxidation (Obach et al., 2004; Obach, 2004), which is catalyzed by AOX1 
(Beedham et al., 1987).  Bazedoxifene was approved by the European Medicines Agency as a 
single agent in 2009 (Conbrizar® product information) and by the U.S. Food and Drug 
Administration in 2013 as a combination product with conjugated estrogens (Genazzani et al., 
2015).  Lasofoxifene was approved by the European Medicines Agency in 2009 and indicated for 
the treatment of osteoporosis in postmenopausal women.  Acolbifene is undergoing late-stage 
clinical trials (Fabian et al., 2015).  Currently, it is not known whether the indole and benzopyran 
classes of SERMs (Supplemental Fig. S1), which differ from the triphenylethylene, 
benzothiophene, tetrahydronaphthalene classes of SERMs in their structural scaffold and 
substituents (Bansal and Lau, 2019), inhibit the catalytic activity of AOX1.   
In the present study, the primary objectives were to: 1) compare and contrast the effect of 
acolbifene (a benzopyran), bazedoxifene (an indole), and lasofoxifene (a tetrahydronaphthalene), 
on the catalytic activity of AOX1, as assessed by carbazeran 4-oxidation (Xie et al., 2019) catalyzed 
by human tissue cytosol and recombinant AOX1 enzyme; 2) determine whether the structural 
analogues (Supplemental Fig. S1) of bazedoxifene and lasofoxifene are inhibitors of AOX1; 3) 
explore how these SERMs bind to AOX1 active site, as evaluated by molecular docking analyses; 
and 4) investigate the effect of estrone sulfate and estrone on the extent of AOX1 inhibition by 
bazedoxifene, given that bazedoxifene is administered clinically in combination with conjugated 
estrogens.  Our in vitro and in silico data provide new molecular insights into the interaction 
between specific SERMs and human AOX1. 
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Materials and Methods 
Chemicals, Reagents, and Enzymes.  Acolbifene and arzoxifene hydrochloride were 
purchased from AdooQ Bioscience (Irvine, CA, USA).  Carbazeran, 4-oxo-carbazeran (also known 
as 4-hydroxycarbazeran), bazedoxifene N-oxide, des(1-azepanyl)ethylbazedoxifene, lasofoxifene, 
racemic 7-methoxylasofoxifene, cis-4-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-
naphthalenyl)phenol, and nafoxidine were purchased from Toronto Research Chemicals, Inc. 
(North York, ON, Canada).  Bazedoxifene acetate, tamoxifen, raloxifene, toremifene citrate, 
ospemifene, clomifene citrate, hydralazine, sodium valproate, tolbutamide, and dimethylsulfoxide 
(DMSO) were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA).  Droloxifene citrate 
was purchased from Abcam (Cambridge, UK).  All other commercially available chemicals were 
of analytical or high performance liquid chromatographic grade.  Rabbit anti-AOX1 primary 
antibody (catalog #TA321294) and recombinant human AOX1 (catalog #TP319221) for protein 
quantification were purchased from OriGene Technologies, Inc. (Rockville, MD, USA).  
Horseradish peroxidase-conjugated anti-rabbit secondary antibody (catalog #043-426) and Rabbit 
(12-180 kDa) Size Separation Master Kit (catalog #CBS-01-01) were bought from ProteinSimple 
(San Jose, CA, USA).  
Human liver cytosol (mixed gender; pool of 150 donors; 20 mg/ml; catalog #452115, lot 
#38290, Gentest® brand; 75 males and 75 females) was purchased from Corning, Inc. (Corning, 
NY, USA).  Human kidney cytosol (mixed gender; pool of 4 donors; 5 mg/ml; catalog #H0610.RC, 
lot #1310121) and human lung cytosol (non-smokers; mixed gender; pool of 4 donors; 5 mg/ml; 
catalog #H0610.PC(NS), lot #1310100) were purchased from Sekisui XenoTech, LLC (Kansas 
City, KS, USA).  Human recombinant AOX1 enzyme (catalog #CYP150, lot #150011B) and 
control cytosol (isolated from Escherichia coli host cells; catalog #CYP099, lot #INT016E18C) 
were purchased from Cypex Ltd. (Dundee, Scotland, UK). 
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Carbazeran 4-Oxidation Assay.  Incubation mixture (200 µl for assays containing human 
liver cytosol or 100 µl for assays containing human kidney cytosol, lung cytosol, or recombinant 
AOX1) consisted of potassium phosphate buffer (100 mM, pH 7.4), carbazeran, and an enzyme.  
The final concentration of DMSO in all samples was 1% v/v, which was shown not to affect the 
AOX1 activity (Behera et al., 2014).  Each incubation mixture was pre-warmed for 3 min at 37°C 
in a shaking water bath.  Enzymatic reaction was initiated by adding liver cytosol (20 µg, 0.1 mg/ml 
final concentration), kidney cytosol (200 µg, 2 mg/ml final concentration), lung cytosol (150 µg, 
1.5 mg/ml final concentration), or recombinant AOX1 (30 µg, 0.3 mg/ml final concentration).  The 
mixture was incubated for 5 min (liver cytosol), 75 min (kidney and lung cytosol), or 15 min 
(recombinant AOX1).  The reaction was terminated by adding an equal volume (200 µl or 100 µl) 
of ice-cold acetonitrile containing tolbutamide (25 nM final concentration; internal standard).  Each 
sample was mixed and placed immediately in an ice bath.  After centrifugation at 16,000 × g for 
15 min at 4°C, the supernatant was transferred to a 96-well microplate for analysis of 4-oxo-
carbazeran and tolbutamide by ultra-high performance liquid chromatography-tandem mass 
spectrometry (UPLC-MS/MS).  To construct a calibration curve for each experiment, 4-oxo-
carbazeran stock solutions (1–1000 µM in DMSO) were freshly added to the incubation mixture 
to give final concentrations of 1–1000 nM (0.2 to 200 pmol; in 0.1% v/v DMSO), and subjected to 
the same procedures as described above.  
O6-Benzylguanine 8-Oxidation Assay.  The assay was conducted according to our 
previous study (Xie et al., 2019), except that the substrate concentration was 5-600 µM, the 
incubation time was 75 min, and the enzymatic reaction was initiated by adding kidney cytosol 
(200 µg, 2 mg/ml final concentration).   
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Quantification of 4-Oxo-Carbazeran by UPLC-MS/MS.  The UPLC-MS/MS system 
and the chromatographic and mass spectrometric conditions for analyzing 4-oxo-carbazeran and 
tolbutamide was reported in detail in our previous study (Xie et al., 2019).  A calibration curve was 
constructed using weighted (1/x2) linear least-squares regression analysis of the peak area ratio (4-
oxo-carbazeran to tolbutamide) versus amount of the metabolite standard added into the incubation 
mixture.   
Enzyme Kinetics Analysis of Carbazeran 4-Oxidation.  Enzyme kinetic experiment was 
performed by conducting the carbazeran 4-oxidation assay at substrate concentrations ranging from 
0.125-32 µM for human liver cytosol, 0.5-40 µM for human kidney cytosol, 1-32 µM for human 
lung cytosol, and 1-80 µM for recombinant AOX1 enzyme.  The velocity (V)-versus-substrate 
concentration (S) data were analyzed by non-linear least-squares regression analysis and fitted to 
several models (Michaelis-Menten, Hill, substrate inhibition, and substrate activation) using 
SigmaPlot version 12.5 (Systat Software Inc., San Jose, CA, USA).  Based on visual inspection 
and various measures of goodness of fit, including Akaike information criterion, coefficient of 
determination (R2), and standard deviation of residuals (Sy.x), the values of maximum velocity 
(Vmax) and the substrate concentration at half the maximum velocity (apparent Km) were calculated 
using the Michaelis-Menten model: 𝑉𝑉 = 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉
𝐾𝐾𝑉𝑉+𝑆𝑆
 or the substrate inhibition model: 𝑉𝑉 = 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉
1+𝐾𝐾𝑉𝑉/𝑆𝑆+𝑆𝑆/𝐾𝐾𝐾𝐾, 
where Ki represents the equilibrium dissociation constant between the substrate and the binding site 
of the enzyme.  The turnover number (kcat), unbound fraction (fu), corrected Km, and unbound 
intrinsic clearance (Clint,u) were calculated as described in our previous study (Xie et al., 2019).  
Enzyme Inhibition Experiments.  Enzyme inhibition was determined by conducting the 
carbazeran 4-oxidation assay in the presence of a SERM, a positive control, a negative control, or 
the vehicle (DMSO) at concentrations specified in each figure legend.  Raloxifene, a known potent 
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AOX1 inhibitor (Obach, 2004), was used as a positive control, whereas valproic acid was included 
as a negative control (Obach et al., 2004).  In the concentration-response experiment, the incubation 
was conducted in the presence of varying concentrations of each chemical in human liver cytosol 
as described in each figure legend.  The half-maximal inhibitory concentration (IC50) value was 
determined by non-linear regression analysis using Sigmaplot 12.5 with the equation:   
]])log[[(log
0max
0 50101 exHillSclopIIC
EEEEffect
−+
−
+=  
where I is the inhibitor concentration, E0 is the minimum effect, and Emax is the maximum effect. 
To determine the enzyme kinetics of the inhibition of the enzyme by SERMs, the 
carbazeran 4-oxidation assay was conducted in the presence of multiple concentrations (0.5, 1, 2, 
or 4 µM) of carbazeran and multiple concentrations of a SERM (bazedoxifene, lasofoxifene, 
tamoxifen, or raloxifene), as specified in the figure legend.  The apparent Ki (apparent equilibrium 
dissociation constant for the enzyme-inhibitor complex) value and mode of inhibition were 
determined by non-linear least-squares regression analysis of the metabolite formation data at 
various concentrations of the inhibitor and substrate, using equations for full and partial 
competitive, noncompetitive, uncompetitive, and mixed-mode inhibition (Sigmaplot 12.5).  The 
best-fit model was determined by Akaike information criterion, R2, and visual inspection of the 
data in the Lineweaver-Burk plot.  The equations for the full competitive inhibition model 
(Equation 1) and the full noncompetitive inhibition model (Equation 2) are: 
𝑣𝑣 = 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉
1+(𝐾𝐾𝑉𝑉/𝑆𝑆)∗(1+𝐼𝐼/𝐾𝐾𝐾𝐾)   Equation 1 
𝑣𝑣 = 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉(1+𝐼𝐼/𝐾𝐾𝐾𝐾)∗(1+𝐾𝐾𝑉𝑉/𝑆𝑆)   Equation 2 
where S represents the substrate concentration, I represents the inhibitor concentration, Vmax 
represents the apparent maximum reaction velocity, Km represents the substrate concentration at 
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which the reaction rate is half of Vmax, and Ki represents the apparent equilibrium dissociation 
constant for the enzyme–inhibitor complex. 
Time-Dependent Inhibition Experiment.  Primary incubation mixture (200 µl) contained 
potassium phosphate buffer (100 mM, pH 7.4), human liver cytosol (100 µg, 0.5 mg/ml), and a 
SERM (acolbifene, bazedoxifene, lasofoxifene, or tamoxifen, each at 10 μM), a positive control 
(hydralazine, 10 μM) (Strelevitz et al., 2012), a negative control (raloxifene, 0.02 μM) (Obach, 
2004), or vehicle (DMSO, 0.5% v/v).  The mixture was pre-warmed for 3 min at 37°C in a shaking 
water bath and the reaction was initiated by adding the enzyme.  At 0 and 30 min after preincubation, 
an aliquot (10 µl) from the primary incubation mixture was transferred to 190 µl of pre-warmed 
(for 3 min at 37°C) secondary incubation mixture (total volume of 200 µl) containing potassium 
phosphate buffer and carbazeran (16 µM).  The enzymatic reaction in the secondary incubation 
mixture was incubated for 5 min at 37°C and terminated by adding 200 µl ice-cold acetonitrile 
containing tolbutamide (25 nM final concentration; internal standard).  The samples were 
processed in the same manner as that described in Section 2.2. 
Molecular Docking.  The structure of the AOX1 protein was obtained from the crystal 
structure of human AOX1 [Protein Data Bank (PDB): 4UHW chain A] (Coelho et al., 2015) at 
98.9% identity to the protein sequence (UniProt AC Q06278).  The molecular docking 
methodology involved contending with the presence of a molybdenum cofactor and several open 
side channels, as well as a relative scarcity of co-crystallized ligands. To simulate electrostatic 
interactions in this binding site, a mix of partial charge methods was adopted, applying a charge 
transfer method, QTPIE (Chen and Martinez, 2007) to the chemically-unusual 
dioxothiomolybdenum (VI) ion (MOS residue), and Antechamber (Wang et al., 2006) for 
assignment of the other protein charges. The sulphur atom in the MOS residue was manually 
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protonated. Ligand charges were assigned using an approximation of the Amber AM1-BCC 
method, called "EEM-Cheminf-HF-MPA" (Geidl et al., 2015) For the five compounds - 
bazedoxifene, lasofoxifene, tamoxifen, acolbifene, and raloxifene, an extensive (~10 hour) docking 
simulation was applied with constraints, allowing ligands to be flexible but with fixed amino acid 
side-chains, optimizing a customized CHEMPLP objective function using the PLANTS program 
(Korb et al., 2009). The constraints were placed in the side sub-pockets and acted to guide the 
ligand towards the binding sub-pocket as observed in the 4-[5-(2,6-dioxo-1,2,3,6-
tetrahydropyridin-4-yl)-1H-1,2,4-triazol-3-yl]-6-oxo-1,6-dihydropyridine-2-carbonitrile (FYO) 
interactions with the crystal structure for bovine xanthine oxidase (PDB:3AM9).  Subsequently, 
for the five compounds, along with their chemically-related derivatives – the bazedoxifene 
derivatives des(1-azepanyl)ethylbazedoxifene and bazedoxifene N-oxide, and the lasofoxifene 
derivatives 7-methoxylasofoxifene, cis-4-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-
naphthalenyl)phenol, and nafoxidine – an energy minimization was performed in which the initial 
pose was based on superposition with the result of the first docking run (Kawabata, 2011).  For this 
energy minimization, the ligand was fixed and receptor side-chains were allowed to be fully 
flexible.   
AOX1 Protein Quantification by a Capillary Nano-proteomic Immunoassay.  The 
amount of AOX1 in cytosols was quantified in a capillary nano-proteomic immunoassay 
(SimpleWestern System, ProteinSimple) as described in our previous study (Xie et al., 2019).   
Statistical Analysis.  Data were analyzed by one-way or two-way analysis of variance and, 
where appropriate, was followed by the Student-Newman-Keuls multiple comparison test 
(SigmaPlot 12.5).  The level of statistical significance was set a priori at p < 0.05. 
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Results 
Enzyme Kinetics of Carbazeran 4-Oxidation Catalyzed by Human Tissue Cytosols 
and Recombinant AOX1 Enzyme.  Experiments were performed to determine the linear range of 
the carbazeran 4-oxidation assay with respect to the amount of cytosolic protein (Supplemental 
Fig. S2) and incubation time (Supplemental Fig. S3) in different types of human tissue cytosol and 
recombinant AOX1.  Shown in Supplemental Table S1 are the assays conditions used in the 
carbazeran 4-oxidation assay.  The catalysis of carbazeran 4-oxidation by liver cytosol, lung 
cytosol, and recombinant AOX1 followed the Michaelis-Menten model, whereas that by kidney 
cytosol followed the substrate inhibition model (Supplemental Fig. S4A-S4D).  As shown in 
Supplemental Table S2, the turnover number (kcat) was considerably greater in liver cytosol than 
in kidney and lung cytosol.  The same rank order also occurred in the abundance of AOX1 protein 
in these cytosol samples.  Liver cytosol, kidney cytosol, lung cytosol, and recombinant AOX1 
enzyme catalyzed carbazeran 4-oxidation with corrected Km at low micromolar concentrations.  
Liver cytosol was also considerably more efficient than kidney cytosol and lung cytosol in 
catalyzing carbazeran 4-oxidation, as assessed by the unbound intrinsic clearance (Clint,u).  The 
relative difference in the Clint,u in liver cytosolic and kidney cytosolic carbazeran 4-oxidation was 
similar to that obtained in liver cytosolic and kidney cytosolic O6-benzylguanine 8-oxidation 
(Supplemental Table S2), which is another catalytic marker of human AOX1 (Xie et al., 2019).  As 
expected, the Escherichia coli cytosol, which was the control for the recombinant AOX1 enzyme, 
did not yield any metabolite (data not shown).   
Effects of SERMs on Carbazeran 4-Oxidation Catalyzed by Human Tissue Cytosol 
and Recombinant AOX1.  To investigate whether acolbifene, bazedoxifene, and lasofoxifene 
inhibit AOX1 activity and compare their effects with those of other SERMS (tamoxifen, 
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toremifene, ospemifene, droloxifene, clomifene, raloxifene, and arzoxifene), liver cytosol was 
incubated with a SERM (25 μM) at a substrate concentration (3 µM) that was near the apparent Km 
value.  As shown in Fig. 1, acolbifene, bazedoxifene, lasofoxifene, tamoxifen, toremifene, 
ospemifene, droloxifene, clomifene, raloxifene, and arzoxifene decreased liver cytosolic 
carbazeran 4-oxidation by 26%, 98%, 98%, 88%, 91%, 89%, 94%, 60%, 100%, and 67%, 
respectively.  In contrast, acolbifene showed only little or no inhibition of liver cytosolic carbazeran 
4-oxidation.    
Additional experiments were performed to determine the inhibitory effect of acolbifene, 
bazedoxifene, and lasofoxifene on carbazeran 4-oxidation catalyzed by human kidney cytosol and 
recombinant AOX1.  Each of these drugs inhibited carbazeran 4-oxidation catalyzed by human 
kidney cytosol (Supplemental Fig. S5A) and recombinant AOX1 (Supplemental Fig. S5B).  The 
magnitude of the inhibition was similar to that occurred in enzymatic incubations containing liver 
cytosol (Fig. 1).  By comparison, tamoxifen, raloxifene, but not valproic acid (negative control), 
inhibited carbazeran 4-oxidation by kidney cytosol (Supplemental Fig. S5A) or recombinant 
AOX1 enzyme (Supplemental Fig. S5B).  Given that the acolbifene, bazedoxifene, and 
lasofoxifene inhibited carbazeran 4-oxidation catalyzed by various tissue cytosols and recombinant 
AOX1 in a similar pattern (Fig. 1 and Supplemental Fig. S5A and S5B), subsequent inhibition 
experiments were conducted with liver cytosol. 
Concentration-Response Relationship in the Inhibition of Human Liver Cytosolic 
AOX1-Mediated Carbazeran 4-Oxidation by Acolbifene, Bazedoxifene, and Lasofoxifene: 
Comparison with Tamoxifen and Raloxifene.  To determine the inhibitory potency (IC50) and 
the minimum inhibitory concentration of acolbifene, bazedoxifene, lasofoxifene, tamoxifen, or 
raloxifene in the inhibition of AOX1 catalytic activity, a concentration-response experiment was 
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conducted with varying concentrations of each SERM.  As shown in Fig. 2A-2E, these SERMs 
decreased carbazeran 4-oxidation in a concentration-dependent manner, and with a sigmoidal 
shaped concentration-response curve.  Among the SERMs investigated, raloxifene was the most 
potent (IC50 = 0.028 µM), whereas bazedoxifene, lasofoxifene, and tamoxifen inhibited the activity 
with IC50 values of 0.19 µM, 0.30 µM, and 7.30 µM, respectively (Table 1).  In contrast, acolbifene 
did not completely inhibit AOX1 activity at the highest concentration tested and was the least 
potent inhibitor of AOX1 (IC50 value of 29.5 µM).  Raloxifene, bazedoxifene, and lasofoxifene 
had comparable minimum AOX1 inhibitory concentrations (0.001-0.03 µM), but they were 0.1-
0.3% of those for tamoxifen and acolbifene (Table 1). 
Mode of Inhibition of Human Liver Cytosolic AOX1-Mediated Carbazeran 4-
Oxidation by Bazedoxifene, Lasofoxifene, Tamoxifen, and Raloxifene.  To determine the 
apparent Ki and mode of inhibition of carbazeran 4-oxidation, liver cytosol was incubated with 
various concentrations of substrate and a SERM.  Based on the nonlinear regression analysis and 
Lineweaver-Burk plots (Fig. 3A-3D), bazedoxifene, lasofoxifene, and tamoxifen inhibited 
carbazeran 4-oxidation by a competitive mode, whereas raloxifene inhibited it by a non-
competitive mode.  As shown in Table 2, both bazedoxifene and lasofoxifene yielded 
submicromolar Ki value of 0.14 ± 0.03 µM, whereas tamoxifen was approximately 20 times less 
potent and raloxifene was 5 times more potent than bazedoxifene and lasofoxifene.   
Comparative Effects of a Metabolite and Structural Analogue of Bazedoxifene on the 
Inhibition of Human Liver Cytosolic AOX1-Mediated Carbazeran 4-Oxidation.  The effect 
of bazedoxifene and its metabolite and structural analogue (Supplemental Fig. S1) on the inhibition 
of carbazeran 4-oxidation was compared (Fig. 4A-4C).  Bazedoxifene, bazedoxifene N-oxide, 
des(1-azepanyl)ethylbazedoxifene, each at 25 μM, decreased carbazeran 4-oxidation by 98%, 95%, 
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99%, respectively (Fig. 4A).  The IC50 value for bazedoxifene (0.19 ± 0.04 μM) was less than that 
of bazedoxifene N-oxide (0.29 ± 0.07 μM), but greater than that of des(1-
azepanyl)ethylbazedoxifene (0.10 ± 0.02 μM) (Table 1). 
Comparative Effects of the Structural Analogues of Lasofoxifene on the Inhibition of 
Human Liver Cytosolic AOX1-Mediated Carbazeran 4-Oxidation.  To elucidate the structural 
features of lasofoxifene contributes to the inhibition of AOX1, the effect of three structural 
analogues (7-methoxylasofoxifene, cis-4-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-
naphthalenyl)phenol, and nafoxidine; Supplemental Fig. S1) of lasofoxifene on carbazeran 4-
oxidation was compared.  At 25 µM, lasofoxifene, 7-methoxylasofoxifene, cis-4-(1,2,3,4-
tetrahydro-6-methoxy-2-phenyl-1-naphthalenyl)phenol, and nafoxidine decreased carbazeran 4-
oxidation by 97%, 92%, 46%, and 77%, respectively (Fig. 5A).  Concentration-response 
experiments (Fig. 5B-5D) indicated that the IC50 value for 7-methoxylasofoxifene was 
approximately 5-fold greater than that for lasofoxifene (0.30 ± 0.03 µM), whereas it was 8-fold 
greater than the IC50 value for cis-4-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-
naphthalenyl)phenol and nafoxidine (Table 1). 
Molecular Docking of SERMs and their Structural Analogues to the Active Site of 
Human AOX1.  The investigation of the binding of SERMs and structural analogues to human 
AOX1 by molecular docking revealed that the strong competitive binders demonstrated a 
combination of specific key interactions that the weaker competitively inhibiting compounds did 
not (Table 3 and Fig. 6).  For bazedoxifene (pink, Fig. 6) and lasofoxifene (salmon, Fig. 6), 
hydrogen bonds were predicted between the ligands and the molybdenum cofactor and Asn-1084.  
The binding of bazedoxifine appeared to be particularly strong because of its unique hydrogen 
bond to Glu-888 and its strong van der Waals overlapped with the Phe-885 ring. Phe-885 has 
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previously been predicted to be involved in interactions with substrates of AOX1 (Lepri et al., 
2017).  The weaker competitive binders, tamoxifen (blue, Fig. 6) and acolbifene (purple, Fig. 6) 
lacked these predicted interactions.  Raloxifene (dark blue, Fig. 6) inhibited strongly, but non-
competitively, and it may bind allosterically to the surface of AOX1 at a location similar to the 
binding site for 10-{2-[(2R)-1-methylpiperidin-2-yl]ethyl}-2-(methylsulfanyl)-10H-phenothiazine 
identified in the crystal structures (Coelho et al., 2015).  In this study, it was used to some extent 
as a negative control for docking to this site.  Alternate hydrogen bonds were predicted for 
raloxifene to Lys-893 and Glu-1270, consistent with the observed strong inhibition.   
Another key structural predictor that was found to correlate with the experimental IC50 
values, at least for the competitive inhibitors, was the distance between the ligand central oxygen 
atom and the molybdenum cofactor (O-Mo distance), as summarized in Table 3 and shown in Fig. 
6.  For the tightest bindings, associated with the lowest IC50 values, the O-Mo distance was reduced, 
suggesting more intimate interaction with the catalytic site of the enzyme.  Conversely, SERMs 
with less favourable fitting within this pocket were forced to adopt docked poses which oriented 
their central oxygen atom away from the molybdenum cofactor.  Raloxifene was again the 
exception to the trend, further supporting the different binding mechanism indicated by inhibition 
studies. 
For the study of the binding of the analogues, the binding scores generated by the docking 
algorithm can only sensibly be used as an approximate indication of the relative binding energy of 
closely structurally related compounds.  It can be difficult to globally correlate the predicted 
binding scores of a docking program with experimental IC50 values or to compare binding scores 
from different ligands in substantially different orientations.  However, in the case of the closely 
related bazedoxifene and lasofoxifene and their analogues, there was a positive correlation (r2 = 
0.78) between log IC50 values and binding efficiency (where the binding efficiency = binding score 
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/ mass of ligand) (Fig. 7).  Table 4 details the simulated binding efficiency data for bazedoxifene 
and lasofoxifene and their analogues.  Compared to bazedoxifene, the analogue compound des(1-
azepanyl)ethyl bazedoxifene yielded a relative log (IC50) of 104.2% and a relative binding 
efficiency of 104.5%.  The slightly weaker binder, bazedoxifene N-oxide, yielded a relative log 
(IC50) of 97.3% and a relative binding efficiency of 94.6%.  For the lasofoxifene analogues, an 
important structural difference was observed in the predicted binding: in lasofoxifene (pink), there 
was a hydrogen bond to Asn-1084, whereas in the analogues; for example, nafoxidene (purple), 
this hydrogen bond was not present.  The binding efficiencies, while perhaps less predictive than 
in bazedoxifene, still ranked lasofoxifene as the best of the derivatives, followed by 7-
methoxylasofoxifene.  Overall, a strong relationship was shown between the in silico determination 
of binding efficiency and the in vitro biochemical data for the inhibition of human AOX1 by 
bazedoxifene, lasofoxifene, and their analogues.   
Effect of Conjugated Estrone and Estrone on the Inhibition of Human Liver Cytosolic 
AOX1-Mediated Carbazeran 4-Oxidation by Bazedoxifene.  Bazedoxifene in combination with 
conjugated estrogens (Duavee®), such as estrone sulfate, is approved by the United States Food 
and Drug Administration for the treatment of moderate to severe vasomotor symptoms associated 
with menopause and prevention of postmenopausal osteoporosis (Cada and Baker, 2014).  
Circulating estrone sulfate can be metabolized in vivo to the active form, estrone, by sulfatases.  
Previously, estrone was shown to inhibit aldehyde oxidase (Obach et al., 2004; Obach, 2004).  
Therefore, we compared the effect of estrone sulfate and estrone on the inhibition of AOX1 
catalytic activity by bazedoxifene.  Concentration-response data indicated that estrone was more 
potent than estrone sulfate in decreasing human liver cytosolic 4-oxidation, with experimentally 
derived IC50 values of 0.18 ± 0.01 μM and 258 ± 51 μM, respectively (Fig. 8A).  Estrone at 0.3, 1, 
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3, and 10 μM and estrone sulfate at 300 and 1000 μM enhanced the inhibitory effect of 
bazedoxifene on human liver cytosol-catalyzed carbazeran 4-oxidation (Fig. 8B). 
Effect of Preincubation of Human Liver Cytosol with a SERM on AOX1-Mediated 
Carbazeran 4-Oxidation.  To investigate whether acolbifene, bazedoxifene, and lasofoxifene 
exhibit time-dependent inhibition of AOX1, each of these SERMs was preincubated with liver 
cytosol for 30 min before transferring an aliquot of the primary incubation mixture to a secondary 
incubation mixture containing the substrate (carbazeran).  Preincubation of acolbifene, 
bazedoxifene, lasofoxifene, or tamoxifen with liver cytosol did not increase the extent of AOX1 
inhibition (Supplemental Fig. S6), consistent with the lack of an effect of preincubation on the 
extent of AOX1 inhibition by raloxifene (Obach, 2004).  In contrast, hydralazine, a known time-
dependent inhibitor of AOX1 (Strelevitz et al., 2012), yielded the expected result (Supplemental 
Fig. S6).   
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Discussion 
A novel aspect of the present study is the differential inhibitory effect of SERMs on the 
catalytic activity of human liver cytosolic AOX1.  The rank order in the potency (based on IC50 
values) of SERM inhibition of AOX1 was raloxifene > bazedoxifene ~ lasofoxifene > tamoxifen 
> acolbifene.  Bazedoxifene and lasofoxifene inhibited AOX1 with apparent Ki values at 
submicromolar concentrations.  These two SERMs were 20 times more potent than tamoxifen and 
5 times less potent than raloxifene.  Lasofoxifene, bazedoxifene, and tamoxifen inhibited AOX1 
activity by a competitive mode, whereas raloxifene inhibited it by a non-competitive mode.  
Raloxifene inhibits human liver cytosol-catalyzed oxidation of vanillin, phthalazine, and nicotine-
Δ1′(5′)-iminium ion in an uncompetitive manner (Obach, 2004), whereas it inhibits the oxidation 
of N-[(2-dimethylamino)ethyl]acridine-4-carboxamide by a competitive mode (Barr and Jones, 
2013).  Collectively, these results indicate a degree of selectivity in human AOX1 inhibition by 
SERMs and their mode of AOX1 inhibition appears to be substrate-dependent. 
The potency of AOX inhibition by raloxifene has been linked to the bisphenol structure and 
the hydrophobic alkylamino side chain of this SERM (Obach, 2004).  These essential features are 
conserved in the structure of bazedoxifene, whereas lasofoxifene possesses a monophenol and an 
alkylamino side chain, which were shown to retain potent inhibitory activity.  In contrast, 
acolbifene has the essential features of a bisphenol structure and alkylamino side chain.  However, 
it was identified as a relatively weak inhibitor and the least potent among the SERMs investigated 
in the present study.  Despite these shared structural elements, acolbifene possesses a six-
membered pyran ring, whereas raloxifene and bazedoxifene have a five-membered thiophene and 
pyrrole ring, respectively. These suggest that the type of backbone structures play a role in AOX1 
inhibition by this class of drugs, although with differing degree of potency and efficacy.  
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Alternatively, the orientation of the alkylamino side chain or the type of side chain in acolbifene 
may influence the binding to the enzyme and decreases the extent of AOX1 inhibition by 
acolbifene.  The findings of our molecular docking simulations were in broad agreement with our 
inhibition data.  Correlative trends exist between the in vitro and in silico data, particularly between 
the measured IC50 values for the competitive inhibitors and the involvement of the molybdenum 
cofactor and key residues in ligand binding, and also in the indication of a notably different binding 
mechanism for the noncompetitive inhibitor raloxifene. 
Another important finding of the present study is that N-oxidation and removal of the 1-
(azepanyl)ethyl moiety affect the inhibitory potency of bazedoxifene.  The IC50 in the inhibition of 
AOX1 by bazedoxifene N-oxide was greater than that of bazedoxifene, indicating that the N-oxide 
group decreases the potency of bazedoxifene, whereas the IC50 value of des(1-
azepanyl)ethylbazedoxifene was less than that of bazedoxifene, indicating that the loss of the 1-
(azepanyl)ethyl moiety increases the potency of bazedoxifene.  A large positive correlation exists 
between the measured IC50 values and the calculated binding efficiency values obtained for these 
compounds from the docking analyses.  In another study (Barr et al., 2015), the investigators 
developed a quantitative structure-activity relationship based on a homology model of human 
AOX1 derived from the crystal structure of mouse AOX3 (PDB ID 3ZYV) (Coelho et al., 2012).  
They concluded that dipole, hydrophilic solvent-accessible surface area and hydrogen bonding-
accepting capacity were descriptors that explained the inhibitory potency of naturally-occurring 
chemicals, such as flavanoids, catechin, stillbenoid, and coumarin (Barr et al., 2015).  The 
importance of hydrogen bonding is reiterated in our study.   
The present study identified for the first time the structural features of lasofoxifene that 
contribute to its potent inhibition of AOX1 activity.  The C7 hydroxyl group is the most important 
for the inhibitory potency of lasofoxifene based on the following experimental evidence: 1) a sole 
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switch of C7 hydroxyl group to methoxy group in 7-methoxylasofoxifene resulted in attenuation of 
AOX1 inhibition, and the IC50 value of 7-methoxylasofoxifene was ~5 times greater than that of 
lasofoxifene; and 2) both cis-4-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthalenyl)phenol 
and nafoxidine, which possess a C7 methoxy group instead of the hydroxyl group, inhibited 
carbazeran 4-oxidation to a lesser extent compared to lasofoxifene and their IC50 values were ~8 
times greater than that of lasofoxifene.  The molecular docking results support the importance of 
the C7 hydroxyl group for the binding of lasofoxifene, from where a hydrogen bond to Asn-1084 
is identified. This hydrogen bond is lost in all the lasofoxifene analogues where the C7 hydroxyl 
group is modified.  The substituted pyrrolidine ring is also important for the inhibition of AOX1 
by lasofoxifene because further attenuation of the inhibitory activity was observed when the 
substituted pyrrolidine ring was removed in cis-4-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-
naphthalenyl)phenol, as compared to 7-methoxylasofoxifene.  Though the pyrrolidine ring 
appeared to be less essential than the C7 hydroxyl group because of the comparable IC50 values of 
7-methoxylasofoxifene and cis-4-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthalenyl)phenol.  
In contrast, the addition of a double bond in nafoxidine did not change the extent of inhibition or 
the IC50 value, as compared to 7-methoxylasofoxifene.  The structural modelling again provides 
support, with the absence of a computed hydrogen bond between the central oxygen atom (which 
itself is not present in cis-4-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthalenyl)phenol) and 
the molybdenum cofactor, whereas this bond is maintained for both 7-methoxylasofoxifene and 
nafoxidine where the central oxygen atom is present as it is in lasofoxifene.  
Bazedoxifene in combination with conjugated estrogens, termed as tissue selective estrogen 
complex, is a new approach to treating/preventing menopausal osteoporosis (Pickar et al., 2018).  
Estrone sulfate is the major conjugated estrogen in the combination product containing 
bazedoxifene (Berrodin et al., 2009).  It is also the major circulating form in postmenopausal 
This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on July 9, 2019 as DOI: 10.1124/jpet.119.259267
 at A
SPET Journals on Septem
ber 6, 2019
jpet.aspetjournals.org
D
ow
nloaded from
 
JPET #259267   
 23 
women (Marchand et al., 2018).  Estrone was shown as a potent inhibitor of AOX1 with an IC50 
value of 0.43 μM (using phthalazine oxidation) in a previous study (Obach, 2004) and 0.18 μM 
(using carbazeran 4-oxidation) in the present study, whereas the present study shows that the 
sulfated form of estrone was only a weak AOX1 inhibitor with IC50 value at high micromolar range.  
Estrone at 0.3-10 μM enhanced the inhibitory effect of bazedoxifene, whereas estrone sulfate 
enhanced the effect of bazedoxifene only at high micromolar concentrations.  The in vivo 
concentration of unconjugated estrone in humans is in the nanomolar range (~10 nM or 2.6 ng/ml) 
(Food and Drug Administration, 2013). Therefore, in vivo, estrone and its sulfate form are not 
expected to enhance the extent of AOX1 inhibition by bazedoxifene. 
Pharmacokinetic studies of SERM conducted on human volunteers have indicated maximal 
plasma concentrations of 6.2-7.2 ng/ml (~0.015 μM) for bazedoxifene (McKeand, 2017), 6.43 
ng/ml (0.0155 μM) for lasofoxifene (Gardner et al., 2006), 164-494 ng/ml (0.44-1.33 μM) for 
tamoxifen (Morello et al., 2003), and 1.36 ng/ml (0.003 μM) for raloxifene (Food and Drug 
Administration, 2007).  SERMs are well-distributed and concentrated in the liver (Morello et al., 
2003).  Although the in vivo concentrations of SERMs in human liver are not known, the 
concentrations of bazedoxifene, lasofoxifene, tamoxifen, and raloxifene have been reported to be 
43-55-fold (Chandrasekaran et al., 2010), 14-25-fold (Prakash et al., 2008), ~40-60-fold (Lien et 
al., 1991), and 8-fold (Lindstrom et al., 1984) greater in rat liver than in plasma, respectively.  If 
these SERMs are concentrated to a similar extent in human liver, the hepatic concentration of 
bazedoxifene, lasofoxifene, tamoxifen, and raloxifene is estimated to be 0.73, 0.39, 80, and 0.023 
μM, respectively.  Overall, our reported apparent Ki values for bazedoxifene, lasofoxifene, 
tamoxifen, and raloxifene (Table 2) suggest potential hepatic drug interactions with AOX1 
substrates.   
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In summary, SERMs differentially inhibited the catalytic activity of human AOX1.  
Bazedoxifene and lasofoxifene inhibited AOX1-catalyzed carbazeran 4-oxidation by a competitive 
mode, whereas acolbifene, which has a different orientation of the alkylamino side chain, only 
weakly inhibited it.  The inhibitory potency of bazedoxifene was decreased by N-oxidation, 
whereas it was increased by the loss of the 1-(azepanyl)ethyl moiety.  The 7-hydroxy group and 
the substituted pyrrolidine ring of lasofoxifene contributed to the potent inhibition of AOX1 by 
lasofoxifene.  Estrone and its sulfated form are not expected to increase any potential in vivo 
inhibitory effect of bazedoxifene.  Our findings suggest that bazedoxifene and lasofoxifene may 
interact with other drugs (e.g. methotrexate, idelalisib) or endogenous chemicals (e.g. 
retinaldehyde) (Garattini et al., 2009) known to be human AOX1 substrates.  Future clinical studies 
would be needed to determine whether these interactions occur in vivo.  To date, studies have been 
reported on AOX1 protein structure-drug metabolism relationships to predict human AOX1 
substrates (Lepri et al., 2017; Cruciani et al., 2018), but limited information on human AOX1 
structure-enzyme inhibitor relationships determined based on the crystal structure of human AOX1 
(Takaoka et al., 2018; Deris-Abdolahpour et al., 2019).  The molecular docking approach 
developed in this study, by virtue of its consistent performance and the ability it allows for 
meaningful comparative analyses of chemical inhibitors, provides a robust in silico framework for 
future investigation of the binding of chemical inhibitors with AOX1.  Therefore, our novel 
biochemical findings, together with molecular docking analyses, provide new insights into the 
differential inhibition of AOX1 by SERMs, how SERMs bind to AOX1, and increase our 
understanding of the AOX1 pharmacophore for the inhibition of AOX1 by drugs and other 
chemicals.  
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Figure Legends 
 
Fig. 1.  Comparative effect of acolbifene, bazedoxifene, lasofoxifene, tamoxifen, toremifene, 
ospemifene, droloxifene, clomifene, raloxifene, and arzoxifene on carbazeran 4-oxidation 
catalyzed by human liver cytosol.  A SERM (25 μM), valproic acid (50 μM; negative control), or 
DMSO (1% v/v; vehicle) was co-incubated with carbazeran (3 μM) and pooled liver cytosol (20 
μg protein) at 37°C for 5 min.  Data are expressed as percentage of activity in the vehicle-treated 
control group and expressed as mean ± S.E.M. of three independent experiments conducted in 
duplicate.  *Significantly different from the vehicle-treated control group (p < 0.05).  The rate of 
reaction in the vehicle-treated control group was 567 ± 18 pmol/min/mg protein.  
 
Fig. 2.  Concentration-response relationship in the inhibition of human liver cytosolic AOX1-
mediated carbazeran 4-oxidation by acolbifene, bazedoxifene, lasofoxifene, tamoxifen, and 
raloxifene.  Pooled liver cytosol (20 μg protein) was incubated with carbazeran (3 μM) and varying 
concentrations of (A) acolbifene (0.3-300 μM), (B) bazedoxifene (0.0003-25 μM), (C) lasofoxifene 
(0.0003-30 μM), (D) tamoxifen (0.003-100 μM), (E) raloxifene (0.00001-1 μM), or DMSO (1% 
v/v; vehicle) at 37°C for 5 min.  Data are expressed as percentage of activity in the vehicle-treated 
control group and expressed as mean ± S.E.M. of three or four independent experiments conducted 
in duplicate or triplicate.  *Significantly different from the vehicle-treated control group (p < 0.05). 
 
Fig. 3. Lineweaver-Burk plots for inhibition of human liver cytosolic AOX1-mediated carbazeran 
4-oxidation by bazedoxifene, lasofoxifene, tamoxifen, and raloxifene.  Pooled liver cytosol (20 μg 
protein) was incubated with carbazeran (0.5, 1, 2, or 4 μM) and varying concentrations of (A) 
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bazedoxifene (0, 0.1, 0.3, or 1 μM), (B) lasofoxifene (0, 0.1, 0.3, or 1 μM), (C) tamoxifen (0, 1, 3, 
or 10 μM), or (D) raloxifene (0, 0.03, 0.06, or 0.1 μM) at 37°C for 5 min.  Data are expressed as 
percentage of activity in the vehicle-treated control group and expressed as mean ± S.E.M. of four 
to five independent experiments conducted in duplicate.  *Significantly different from the vehicle-
treated control group (p < 0.05). 
 
Fig. 4.  Inhibition of human liver cytosolic AOX1-mediated carbazeran 4-oxidation by 
metabolite/structural analogues of bazedoxifene.  (A) Pooled liver cytosol (20 μg protein) was 
incubated with carbazeran (3 μM) and bazedoxifene, bazedoxifene N-oxide, des(1-
azepanyl)ethylbazedoxifene (each at 25 μM), valproic acid (50 μM; negative control), or DMSO 
(1% v/v; vehicle) at 37°C for 5 min.  (B, C) Pooled liver cytosol (20 μg protein) was incubated 
with carbazeran (3 μM) and varying concentrations of (B) bazedoxifene N-oxide (0.0003-25 μM), 
(C) des(1-azepanyl)ethylbazedoxifene (0.0003-25 μM), or DMSO (1% v/v; vehicle) at 37°C for 5 
min.  Data are expressed as percentage of activity in the vehicle-treated control group and expressed 
as mean ± S.E.M. of three to five independent experiments conducted in duplicate.  *Significantly 
different from the vehicle-treated control group (p < 0.05). 
 
Fig. 5.  Inhibition of human liver cytosolic AOX1-mediated carbazeran 4-oxidation by the 
tetrahydronaphthalene class of SERMs.  (A) Pooled liver cytosol (20 μg protein) was incubated 
with carbazeran (3 μM) and lasofoxifene, 7-methoxylasofoxifene, cis-4-(1,2,3,4-tetrahydro-6-
methoxy-2-phenyl-1-naphthalenyl)phenol, nafoxidine (each at 25 μM), valproic acid (50 μM; 
negative control), or DMSO (1% v/v; vehicle) at 37°C for 5 min.  (B-D) Pooled liver cytosol (20 
μg protein) was incubated with carbazeran (3 μM) and varying concentrations of (B) 7-
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methoxylasofoxifene (0.003-100 μM), (C) cis-4-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-
naphthalenyl)phenol (0.03-30 μM), (D) nafoxidine (0.003-100 μM), or DMSO (1% v/v; vehicle) 
at 37°C for 5 min.  Data are expressed as percentage of activity in the vehicle-treated control group 
and expressed as mean ± S.E.M. of three to seven independent experiments conducted in duplicate.  
*Significantly different from the vehicle-treated control group (p < 0.05). 
 
Fig. 6.  Molecular docking of SERMs and their structural analogues to the active site of human 
AOX1.  The predicted binding of the ten compounds is shown with the molybdenum cofactor 
[MOS, dioxothiomolybdenum (VI) ion] visible towards the centre of each frame and the distance 
between it and the ligand central oxygen atom shown in pink.  The key residues are shown as 
labelled.  Computed hydrogen bonds are shown in light blue. 
 
Fig. 7.  Correlation analysis of the experimentally derived IC50 values in the inhibition of human 
AOX1 by SERM and the in silico generated values in human AOX1 binding efficiency by SERM.  
Experimentally derived IC50 values are shown in Table 1. AOX1 binding efficiency values are 
shown in Table 4.   
 
Fig. 8.  Effect of estrone and estrone sulfate on inhibition of human liver cytosolic AOX1-mediated 
carbazeran 4-oxidation by bazedoxifene.  (A) Pooled liver cytosol (20 μg protein) was incubated 
with carbazeran (3 μM) and varying concentrations of estrone (0.0003-30 μM), estrone sulfate (1-
3000 μM), or DMSO (1% v/v; vehicle) at 37°C for 5 min.  (B) Pooled liver cytosol (20 μg protein) 
was incubated with carbazeran (3 μM) and the combination of bazedoxifene (0.1 μM) with varying 
concentrations of estrone sulfate (30-1000 μM), estrone (0.03-10 μM), or DMSO (1% v/v; vehicle) 
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at 37°C for 5 min.  Data are expressed as percentage of activity in the vehicle-treated control group 
and expressed as mean ± S.E.M. of three or four independent experiments conducted in duplicate.  
*Significantly different from the vehicle-treated control group (p < 0.05).  #Significantly different 
from the bazedoxifene-treated group (p < 0.05).  The bazedoxifene (0.1 μM) group alone inhibited 
carbazeran 4-oxidation by 41 ± 3% in the estrone experiment and 38 ± 4% in the estrone sulfate 
experiment.  
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TABLE 1 
IC50 values and minimum inhibitory concentration in the inhibition of human liver cytosolic AOX1-mediated carbazeran 4-oxidation 
by SERMs and the structural analogues of bazedoxifene and lasofoxifene. 
Data are expressed as mean ± S.E.M. of three to seven independent experiments conducted in duplicate or triplicate.  
Chemical Class Chemical IC50 (µM) Minimum Inhibitory 
Concentration (µM) 
Benzothiophene Raloxifene 0.028 ± 0.004  0.01 
Indole Bazedoxifene 0.19 ± 0.02 0.03 
Tetrahydronaphthalene Lasofoxifene 0.30 ± 0.02 0.03 
Triphenylethylene Tamoxifen 7.30 ± 0.72  10 
Benzopyran Acolbifene 29.5 ± 4.6a 30 
    
Bazedoxifene and Metabolites/Analogues   
Indole Des(1-azepanyl)ethylbazedoxifene 0.10 ± 0.01b 0.003 
Indole Bazedoxifene 0.19 ± 0.02 0.03 
Indole Bazedoxifene N-oxide 0.29 ± 0.04b 0.003 
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Lasofoxifene and Analogues   
Tetrahydronaphthalene Lasofoxifene 0.30 ± 0.02 0.03 
Tetrahydronaphthalene 7-Methoxylasofoxifene 1.56 ± 0.21c 0.003 
Tetrahydronaphthalene 
Cis-4-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-
naphthalenyl)phenol 
2.35 ± 0.24c 3 
Tetrahydronaphthalene Nafoxidine 2.50 ± 0.23c 1 
 
a, Significantly different from the raloxifene group (p < 0.05). 
b, Significantly different from the bazedoxifene group (p < 0.05). 
c, Significantly different from the lasofoxifene group (p < 0.05). 
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TABLE 2 
Apparent Ki values and mode of inhibition of human liver cytosolic AOX1-mediated carbazeran 4-oxidation by bazedoxifene, 
lasofoxifene, tamoxifen, and raloxifene. 
Data are expressed as mean ± S.E.M. for four or five independent experiments conducted in duplicate.   
Chemical Class Chemical Apparent Ki (µM) Mode of Inhibition Ratio of Apparent Ki to Apparent Km  
Benzothiophene Raloxifene 0.028 ± 0.002 Non-competitive (Full) 0.0044 
Tetrahydronaphthalene Lasofoxifene 0.14 ± 0.02 Competitive (Full) 0.02 
Indole Bazedoxifene 0.14 ± 0.02 Competitive (Full) 0.02 
Triphenylethylene Tamoxifen 2.78 ± 0.47a Competitive (Full) 0.44 
 
a, Significantly different from the raloxifene group (p < 0.05). 
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TABLE 3 
Analysis of SERM ligand docking and key interactions with human AOX1. 
Experimental Rank 
(based on IC50) 
Compound O-Mo Distancea 
(Å) 
Key Hydrogen 
Bonds 
Key Rings Key van der Waals 
Interactions 
2 Bazedoxifene 4.453 Glu-888 
Asn-1084 
MOS 
Phe-885 Ala-919 
Ile-1085 
3 Lasofoxifene 4.729 Asn-1084 
MOS 
-- Ala-919 
Ile-1085 
4 Tamoxifen 6.143 -- -- Ile-1085 
5 Acolbifene 7.667 Asn-1084 -- Ile-1085 
1 Raloxifene 10.039 Lys-893 
Glu-1270 
-- -- 
 
aDistance between the ligand central oxygen atom and the molybdenum cofactor 
 
MOS, dioxothiomolybdenum (VI) ion  
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TABLE 4 
Docking analysis in the molecular interaction between human AOX1 and bazedoxifene, lasofoxifene, and their structural analogues. 
Experimental Rank 
(based on IC50) 
Parent Drug and Analogues Log [IC50 (M)] Binding Efficiency 
Bazedoxifene and Analogues   
1 Des(1-azepanyl)ethylbazedoxifene -7.00 -0.938 
2 Bazedoxifene -6.72 -0.897 
3 Bazedoxifene N-oxide -6.54 -0.848 
    
Lasofoxifene and Analogues   
1 Lasofoxifene -6.52 -0.797 
2 7-Methoxylasofoxifene -5.81 -0.790 
3 Cis-4-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthalenyl)phenol -5.63 -0.761 
4 Nafoxidine -5.60 -0.787 
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Supplemental Fig. S1.  Chemical structures of acolbifene, bazedoxifene, lasofoxifene, and select structural analogues.  
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Supplemental Fig. S2.  Carbazeran 4-oxidation catalyzed by human liver cytosol, kidney cytosol, lung cytosol, and recombinant AOX1 
enzyme as a function of amount of cytosolic protein.  (A) Varying amount of liver cytosol (1, 2, 5, 10, 15, 20, or 30 µg protein) was 
incubated with carbazeran (1 µM) at 37C for 3 min.  (B-D) Varying amount of kidney cytosol (0, 25, 50, 100, 150, 200, or 250 µg 
protein) (B), lung cytosol (0, 50, 100, 150, 200, 250, or 300 µg protein) (C), or recombinant AOX1 enzyme (0, 5, 10, 20, 30, 40, 50 µg 
protein) (D) was incubated with carbazeran (16 µM) at 37C for 45 min.  Data are expressed as mean ± S.E.M. of three independent 
experiments.  
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Supplemental Fig. S3.  Carbazeran 4-oxidation catalyzed by human liver cytosol, kidney cytosol, lung cytosol, and recombinant AOX1 
enzyme as a function of incubation time.  (A) Liver cytosol (20 µg protein) was incubated with carbazeran (1 µM) at 37C for 0, 2, 3, 5, 
7, 10, or 15 min.  (B-D) Kidney cytosol (200 µg protein) (B), lung cytosol (150 µg protein) (D), or recombinant AOX1 enzyme (30 µg 
protein) (D) was incubated with carbazeran (16 µM) at 37C for 0, 15, 30, 45, 60, 75, or 90 min.  Data are expressed as mean ± S.E.M. 
of three independent experiments.  
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Supplemental Fig. S4.  Carbazeran 4-oxidation catalyzed by human liver cytosol, kidney cytosol, lung cytosol, and recombinant AOX1 
enzyme.  (A) Pooled liver cytosol (20 μg protein) was incubated with varying concentrations of carbazeran (0.125, 0.25, 0.5, 1, 2, 4, 8, 
16, or 32 μM) at 37°C for 5 min.  (B) Pooled kidney cytosol (200 μg protein) was incubated with varying concentrations of carbazeran 
(0.5, 1, 2, 4, 8, 16, 24, or 40 μM) at 37°C for 75 min.  (C) Pooled lung cytosol (150 μg protein) was incubated with carbazeran (1, 2, 4, 
6, 8, 12, 16, 24, or 32 μM) at 37°C for 75 min.  (D) Recombinant AOX1 enzyme (30 μg protein) was incubated with carbazeran (1, 2, 4, 
8, 16, 24, 40, or 80 μM) at 37°C for 15 min.  Data were analyzed by nonlinear least-squares regression and fitted into the Michaelis-
Menten (A, C, D) or substrate inhibition model (B).  Data are expressed as mean ± S.E.M. of three or four independent experiments 
conducted in duplicate.  
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Supplemental Fig. S5.  O6-Benzylguanine 8-oxidation catalyzed by human liver and kidney cytosol.  (A) Pooled liver cytosol (20 μg 
protein) was incubated with varying concentrations of O6-benzylguanine (1, 2.5, 5, 10, 25, 50, 100, 200, 300, or 400 μM) at 37°C for 5 
min.  (B) Pooled kidney cytosol (200 μg protein) was incubated with varying concentrations of O6-benzylguanine (5, 25, 50, 100, 200, 
400, or 600 μM) at 37°C for 75 min.  Data are expressed as mean ± S.E.M. of three independent experiments. 
  
[O6-Benzylguanine] (µM)
0 200 400 600
O
6 -
B
e n
z y
l g
u a
n i
n e
 8
- O
x i
d a
t i o
n
( p
m
o l
/ m
i n
/ m
g  
p r
o t
e i
n )
0
500
1000
1500
A BHuman Liver Cytosol
[O6-Benzylguanine] (µM)
0 200 400 600
0
1
2
500
1000
1500
Human Kidney Cytosol
JPET #259267.  Supplemental Materials.  Chen et al.       
                              
 7
 
 
 
Supplemental Fig. S6.  Comparative effect of acolbifene, bazedoxifene, lasofoxifene, tamoxifen, and raloxifene on carbazeran 4-
oxidation catalyzed by human kidney cytosol and recombinant AOX1 enzyme.  (A) A SERM (25 μM), valproic acid (50 μM; negative 
control), or DMSO (1% v/v; vehicle) was co-incubated with carbazeran (2 μM) and pooled kidney cytosol (200 μg protein) at 37C for 
75 min.  (B) A SERM (25 μM), valproic acid (50 μM; negative control), or DMSO (1% v/v; vehicle) was co-incubated with carbazeran 
(4 μM) and recombinant AOX1 enzyme (30 μg protein) at 37C for 15 min.  Data are expressed as percentage of activity in the vehicle-
treated control group and expressed as mean ± S.E.M. of three independent experiments conducted in duplicate.  *Significantly different 
from the vehicle-treated control group (p < 0.05).  The rate of reaction in the vehicle-treated control group was 0.50 ± 0.03 pmol/min/mg 
protein (A) and 24 ± 0.7 pmol/min/mg protein (B). 
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Supplemental Fig. S7.  Effect of preincubation of human liver cytosol with SERMs on carbazeran 4-oxidation.  Human liver cytosol 
(100 μg protein) was preincubated with a SERM (10 μM lasofoxifene, 10 μM bazedoxifene, 10 μM acolbifene, 10 μM tamoxifen, 0.02 
μM raloxifene, or 10 μM hydralazine), or vehicle (0.5% v/v DMSO) at 37°C for 0 or 30 min.  An aliquot (10 μl) of the primary incubation 
mixture was incubated with carbazeran (3 μM) for 5 min.  Data are expressed as percentage of activity in the vehicle-treated control 
group that was not subjected to preincubation (1164 ± 52 pmol/min/mg protein) and expressed as mean ± S.E.M. for three independent 
experiments. 
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SUPPLEMENTAL TABLE S1 
Shown are the carbazeran 4-oxidation assay conditions in the AOX1 inhibition experiments.  
Enzyme Source 
Amount of Cytosolic 
Protein (g) 
Incubation Time 
(min) 
Substrate (Carbazeran)  
Concentration (M) 
Human liver cytosol 20 5 3 
Human kidney cytosol 200 75 2 
Human lung cytosol 150 75 N/A 
Human Recombinant AOX1 30 15 4 
 
N/A, not applicable. 
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SUPPLEMENTAL TABLE S2 
Human AOX1 protein content and enzyme kinetics of carbazeran 4-oxidation and O6-benzylguanine 8-oxidation and catalyzed by 
human tissue cytosols or recombinant AOX1. 
Vmax, kcat, apparent Km, corrected Km, and unbound intrinsic clearance (Clint,u) were calculated as described under Materials and Methods.  
Data are expressed as mean ± S.E.M. for three or four independent experiments conducted in duplicate. 
 
Sample 
AOX1 Protein 
Content (pmol/mg 
protein) 
Vmax 
(pmol/min/mg 
protein) 
kcat (min-1) 
Apparent Km 
(μM) 
Corrected Km 
(μM) a 
Clint,u 
(μl/ min/mg 
protein) 
Clint,u 
(μl/ min/pmol 
AOX1) 
Carbazeran 4-Oxidation       
Liver cytosol 63.8 ± 4.5 1290 ± 138 20.2 ± 2.2 6.33 ± 0.66 5.93 ± 0.62 217 ± 5 3.41 ± 0.08 
Kidney cytosol 21.0 ± 1.3 0.77 ± 0.03b 0.04 ± 0.001b 1.63 ± 0.30b 1.52 ± 0.28b 0.55 ± 0.07b 0.03 ± 0.003b 
Lung cytosol 1.8 ± 0.1 0.22 ± 0.02b 0.12 ± 0.01b 3.30 ± 0.44b 3.09 ± 0.41b 0.07 ± 0.01b 0.04 ± 0.004b 
Recombinant AOX1 n.d. 39.1 ± 2.6b N/A 4.1 ± 0.08b 3.8 ± 0.08b 10.3 ± 0.9b N/A 
O6-Benzylguanine 8-Oxidation       
Liver cytosol c 63.8 ± 4.5 1254 ± 102 19.7 ± 1.6 70 ± 8 71 ± 8 18 ± 2 0.28 ± 0.03 
Kidney cytosol 21.0 ± 1.3 1.2 ± 0.1b 0.06 ± 0.005b 46 ± 5b 46 ± 5b 0.03 ± 0.001b 0.001 ± 0.000b 
 
a, fu = 0.94 (carbazeran) or 1.01 (O6-benzylguanine) was used in the calculations of correct Km and Clint,u (Xie et al., 2019). 
b, Significantly different from the human liver cytosol group (p < 0.05). 
c, Data from Xie et al., 2019. 
Turnover number (kcat) was calculated by dividing Vmax by AOX1 protein concentration. 
n.d., not determined. 
LLOQ, lower limit of quantification.  N/A, not applicable. 
